Commentary on "Dysfunctional dendritic cells limit antigen-specific T cell response in glioma"

Robert M Prins^{1

2

3

4}, Richard G Everson^{1

3}

Affiliations

¹ Department of Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
² Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
³ Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
⁴ Parker Institute for Cancer Immunotherapy, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.

Editorial

Robert M Prins et al. Neuro Oncol. 2023.

. 2023 Feb 14;25(2):277-278.

doi: 10.1093/neuonc/noac256.

Robert M Prins^{1

2

3

4}, Richard G Everson^{1

3}

¹ Department of Neurosurgery, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
² Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
³ Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.
⁴ Parker Institute for Cancer Immunotherapy, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA.

No abstract available

Comment on

Dysfunctional dendritic cells limit antigen-specific T cell response in glioma.
Friedrich M, Hahn M, Michel J, Sankowski R, Kilian M, Kehl N, Günter M, Bunse T, Pusch S, von Deimling A, Wick W, Autenrieth SE, Prinz M, Platten M, Bunse L. Friedrich M, et al. Neuro Oncol. 2023 Feb 14;25(2):263-276. doi: 10.1093/neuonc/noac138. Neuro Oncol. 2023. PMID: 35609569 Free PMC article.

1. Friedrich M, Hahn M, Michel J, et al. Dysfunctional dendritic cells limit antigen-specific T cell response in glioma. Neuro Oncol. 2023;25(2):263–276. - PMC - PubMed
1. Salmon H, Idoyaga J, Rahman A, et al. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity. 2016;44(4):924–938. - PMC - PubMed
1. Ferris ST, Ohara RA, Ou F, et al. cDC1 vaccines drive tumor rejection by direct presentation independently of host cDC1. Cancer Immunol Res. 2022;10(8):920–931. - PMC - PubMed
1. Spranger S, Dai D, Horton B, Gajewski TF. Tumor-residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell. 2017;31(5):711–723.e4. - PMC - PubMed
1. Lee AH, Sun L, Mochizuki AY, et al. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nat Commun. 2021;12(1):6938. - PMC - PubMed